Therapeutic Potential of „Derived-Multiple Allogeneic Proteins Paracrine Signaling-D-Mapps” in the Treatment of Dry Eye Disease

1. Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu Z, Nelson JD, Nichols JJ, Tsubota K, Stapleton F. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15:276-283.10.1016/j.jtos.2017.05.00828736335 Search in Google Scholar

2. Milner MS, Beckman KA, Luchs JI, Allen QB, Awdeh RM, Berdahl J, Boland TS, Buznego C, Gira JP, Goldberg DF, Goldman D, Goyal RK, Jackson MA, Katz J, Kim T, Majmudar PA, Malhotra RP, McDonald MB, Rajpal RK, Raviv T, Rowen S, Shamie N, Solomon JD, Stonecipher K, Tauber S, Trattler W, Walter KA, Waring GO 4th, Weinstock RJ, Wiley WF, Yeu E. Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment. Curr Opin Ophthalmol. 2017;27 Suppl 1:3-47.10.1097/01.icu.0000512373.81749.b7534589028099212 Search in Google Scholar

3. Foulks GN, Forstot SL, Donshik PC, Forstot JZ, Goldstein MH, Lemp MA, Nelson JD, Nichols KK, Pflugfelder SC, Tanzer JM, Asbell P, Hammitt K, Jacobs DS. Clinical guidelines for management of dry eye associated with Sjögren disease. Ocul Surf. 2015;13:118-32.10.1016/j.jtos.2014.12.00125881996 Search in Google Scholar

4. Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012;130:90-100.10.1001/archophthalmol.2011.364367772422232476 Search in Google Scholar

5. Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112:71-81.10.3238/arztebl.2015.0071433558525686388 Search in Google Scholar

6. Nguyen LS, Vautier M, Allenbach Y, Zahr N, Benveniste O, Funck-Brentano C, Salem JE. Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation. Drug Saf. 2019;42:813-825.10.1007/s40264-019-00810-930868436 Search in Google Scholar

7. Marshall LL, Roach JM. Treatment of Dry Eye Disease. Consult Pharm. 2016;31:96-106.10.4140/TCP.n.2016.9626842687 Search in Google Scholar

8. Villatoro AJ, Fernández V, Claros S, Alcoholado C, Cifuentes M, Merayo-Lloves J, Andrades JA, Becerra J. Regenerative Therapies in Dry Eye Disease: From Growth Factors to Cell Therapy. Int J Mol Sci. 2017;18(11). pii: E2264.10.3390/ijms18112264571323429143779 Search in Google Scholar

9. Harrell CR, Simovic Markovic B, Fellabaum C, Arsenijevic A, Djonov V, Arsenijevic N, Volarevic V. Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Eye Diseases. Adv Exp Med Biol. 2018;1089:47-57.10.1007/5584_2018_21929774506 Search in Google Scholar

10. Harrell CR, Fellabaum C, Simovic Markovic B, Arsenijevic A, Volarevic V. Therapeutic potential of “Exosomes derived Multiple Allogeneic Proteins Paracrine Signaling: Exosomes d-MAPPS” is based on the effects of exosomes, immunosuppressive and trophic factors. Ser J of Exp Clin Res. 2018; doi:10.2478/sjecr-2018-0032.10.2478/sjecr-2018-0032 Search in Google Scholar

11. Cha SH, Lee JS, Oum BS, Kim CD. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin Exp Ophthalmol. 2004; 32:180-184.10.1111/j.1442-9071.2004.00782.x15068436 Search in Google Scholar

12. Arsenijevic M, Milovanovic M, Jovanovic S, Arsenijevic N, Markovic BS, Gazdic M, Volarevic V. In vitro and in vivo anti-tumor effects of selected platinum(IV) and dinuclear platinum(II) complexes against lung cancer cells. J Biol Inorg Chem. 2017;22:807-817.10.1007/s00775-017-1459-y28421385 Search in Google Scholar

13. Asiedu K, Kyei S, Mensah SN, Ocansey S, Abu LS, Kyere EA. Ocular surface disease index (OSDI) versus the standard patient evaluation of eye dryness (SPEED): a study of a nonclinical sample. Cornea 2016; 35:175-180.10.1097/ICO.000000000000071226655485 Search in Google Scholar

14. Finis D, Pischel N, König C, Hayajneh J, Borrelli M, Schrader S, Geerling G. Comparison of the OSDI and SPEED questionnaires for the evaluation of dry eye disease in clinical routine. Ophthalmologe. 2014;111:1050-1056.10.1007/s00347-014-3042-z25030896 Search in Google Scholar

15. Pflugfelder SC, Corrales RM, de Paiva CS. T helper cytokines in dry eye disease. Exp Eye Res. 2013;117: 118-25.10.1016/j.exer.2013.08.013385583824012834 Search in Google Scholar

16. Semba CP, Gadek TR. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease. Clin Ophthalmol. 2016;10:1083-94. Search in Google Scholar

17. Dohlman TH, Ding J, Dana R, Chauhan SK. T Cell-Derived Granulocyte-Macrophage Colony-Stimulating Factor Contributes to Dry Eye Disease Pathogenesis by Promoting CD11b+ Myeloid Cell Maturation and Migration. Invest Ophthalmol Vis Sci. 2017;58:1330-1336.10.1167/iovs.16-20789534162428241321 Search in Google Scholar

18. Wei Y, Asbell PA. The core mechanism of dry eye disease is inflammation. Eye Contact Lens. 2014;40:248-56.10.1097/ICL.0000000000000042423182825390549 Search in Google Scholar

19. Harrell CR, Simovic Markovic B, Fellabaum C, Miloradovic D, Acovic A, Miloradovic D, Arsenijevic N, Volarevic V. Exo-d-MAPPS attenuates production of inflammatory cytokines and promotes generation of immunosuppressive phenotype in peripheral blood mononuclear cells. Ser J of Exp Clin Res. 2019; doi: 10.2478/sjecr-2019-0045.10.2478/sjecr-2019-0045 Search in Google Scholar

20. Chen HW, Chen HY, Wang LT, Wang FH, Fang LW, Lai HY, Chen HH, Lu J, Hung MS, Cheng Y, Chen MY, Liu SJ, Chong P, Lee OK, Hsu SC. Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines. J Immunol. 2013;190:5065-77.10.4049/jimmunol.120277523589610 Search in Google Scholar

21. Ratay ML, Glowacki AJ, Balmert SC, Acharya AP, Polat J, Andrews LP, Fedorchak MV, Schuman JS, Vignali DAA, Little SR. Treg-recruiting microspheres prevent inflammation in a murine model of dry eye disease. J Control Release. 2017;258:208-217.10.1016/j.jconrel.2017.05.007780556228501670 Search in Google Scholar

22. Chauhan SK, El Annan J, Ecoiffier T, Goyal S, Zhang Q, Saban DR, Dana R. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol. 2009; 182:1247-52.10.4049/jimmunol.182.3.1247263058619155469 Search in Google Scholar

23. Fu R, Jiang Y, Zhou J, Zhang J. Rebamipide ophthalmic solution modulates the ratio of T helper cell 17/regulatory T cells in dry eye disease mice. Mol Med Rep. 2019;19:4011-4018.10.3892/mmr.2019.10068647219430896815 Search in Google Scholar

24. Ge W, Jiang J, Arp J, Liu W, Garcia B, Wang H. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation. 2010;90:1312-20.10.1097/TP.0b013e3181fed00121042238 Search in Google Scholar

25. Harrell CR, Jankovic MG, Fellabaum C, Volarevic A, Djonov V, Arsenijevic A, Volarevic V. Molecular Mechanisms Responsible for Anti-inflammatory and Immunosuppressive Effects of Mesenchymal Stem Cell-Derived Factors. Adv Exp Med Biol. 2019;1084:187-206.10.1007/5584_2018_30631175638 Search in Google Scholar

26. Volarevic V, Zdravkovic N, Harrell CR, Arsenijevic N, Fellabaum C, Djonov V, Lukic ML, Simovic Markovic B. Galectin-3 Regulates Indoleamine-2,3-dioxygenase- Dependent Cross-Talk between Colon-Infiltrating Dendritic Cells and T Regulatory Cells and May Represent a Valuable Biomarker for Monitoring the Progression of Ulcerative Colitis. Cells. 2019 Jul 12;8(7). pii: E709.10.3390/cells8070709667820231336879 Search in Google Scholar

27. Matteoli G, Mazzini E, Iliev ID, Mileti E, Fallarino F, Puccetti P, Chieppa M, Rescigno M. Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. Gut. 2010;59(5):595-604.10.1136/gut.2009.18510820427394 Search in Google Scholar